tiprankstipranks
Opiant Pharmaceuticals Announces FDA Acceptance and Priority Review of NDA for OPNT003, Nasal Nalmefene, for Opioid Overdose
PremiumPress ReleasesOpiant Pharmaceuticals Announces FDA Acceptance and Priority Review of NDA for OPNT003, Nasal Nalmefene, for Opioid Overdose
1y ago
Opiant announces FDA acceptance, priority review of NDA of OPNT003
PremiumThe Fly
Opiant announces FDA acceptance, priority review of NDA of OPNT003
1y ago
Opiant Pharmaceuticals Announces Completion of Rolling NDA Submission for OPNT003, Nasal Nalmefene, for Opioid Overdose
PremiumPress Releases
Opiant Pharmaceuticals Announces Completion of Rolling NDA Submission for OPNT003, Nasal Nalmefene, for Opioid Overdose
1y ago
Indivior To Acquire Opiant Pharmaceuticals
PremiumPress ReleasesIndivior To Acquire Opiant Pharmaceuticals
1y ago
Indivior To Acquire Opiant Pharmaceuticals
PremiumPress Releases
Indivior To Acquire Opiant Pharmaceuticals
1y ago
Indivior PLC to Acquire Opiant Pharmaceuticals
PremiumPress Releases
Indivior PLC to Acquire Opiant Pharmaceuticals
1y ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100